What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies

Statement of Need
Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. While there are currently no approved therapies for the treatment of NASH, several targeted therapies are being investigated in clinical trials, with high probability of being approved in the near future. Hence, it is imperative that hepatologists and gastroenterologists have up to date knowledge regarding the latest clinical data on NASH therapies.

This CME Outfitters webcast features expert faculty integrating augmented reality (AR) to discuss pathways, therapeutic targets, and disease progression providing the learners with the best visual experience to enable them to integrate the latest tools for diagnosis and management of patients with NASH.

Learning Objectives

At the end of this CE activity, participants should be able to:
- Describe the role of immune, inflammatory, and metabolic pathways in the pathogenesis of NASH.
- Select appropriate non-invasive and invasive modalities for the identification of advanced fibrosis in patients with NAFLD.
- Evaluate the efficacy of emerging therapies for improving fibrosis in patients with NASH.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe the role of immune, inflammatory, and metabolic pathways in the pathogenesis of NASH.
- Determine appropriate non-invasive and invasive modalities for the identification of advanced fibrosis in patients with NAFLD.
- Evaluate the efficacy of emerging therapies for improving fibrosis in patients with NASH.